It was recently learned that Hefei Breath Medical Co., Ltd. (abbreviated as Qihao Medical) announced that it has completed a series B financing of tens of millions of yuan. The original shareholder Anhui Huaying Capital, and the new investment institution Anhui Chuanggu Capital and Baidu Ventures will jointly invest Finish.
Previously, Qihao Medical completed pre-A round and A round financing of tens of millions of yuan in 2019 and the second half of 2020, basically maintaining the annual financing rhythm, and continued to be recognized by the capital side for investment. The company's continuous innovation of new products and new technology applications on the ENT circuit, especially the in-depth research and development of polymer medical materials, reflects the strong independent research and development capabilities and technological innovation capabilities of Qihao Medical.
Despite the impact of the epidemic, the field of otolaryngology, head and neck surgery in China is still developing rapidly. The volume of operations has increased year by year. It has become a new force in the medical device segment, and its market size has reached nearly tens of billions of yuan.
Since its establishment in 2017, Qihao Medical has been committed to the product development, production and sales of otolaryngology circuit. The company has formed three core products: low-temperature plasma surgery system, fully degradable sinus drug stent system, degradable expansion hemostasis Mian has entered clinical trials (completed), more than 100 clinical trials have been enrolled, and clinical trials have begun enrollment.
It is worth mentioning that the first domestic nasal drug delivery device (nasal medical nebulizer) launched by Qihao Medical has also applied for a registration certificate with the Anhui Provincial Food and Drug Administration.
In the future, Qihao Medical will continue to rely on the "Chinese Science Qihao Biomedical Material Technology Joint Laboratory" jointly established with the Lanzhou Institute of Physical Chemistry, Chinese Academy of Sciences, and Shanghai Children’s Hospital, PLA General Hospital, Shanghai Sixth Hospital, and China Science and Technology The First Affiliated Hospital of the University, the First Affiliated Hospital of Anhui Medical University, Nanjing Provincial People's Hospital, Peking Union Medical College Hospital, Peking University People's Hospital and other famous domestic hospitals such as otolaryngology experts and professors cooperated and innovated, and continued to exert their strength in the otolaryngology circuit. Qihao Medical will continue to develop and innovate a number of brand-new three-category products used exclusively by domestic ENT departments to serve doctors, benefit patients, and continue to lead the domestic ENT circuit.
Investors say: The otolaryngology market is growing rapidly,
Qihao Medical's multiple innovative products occupy the high ground of the industry
Regarding the investment in Qihao Medical, Huaying Capital, the investor in this round, responded: Huaying Investment is optimistic about the development prospects of domestic medical technology for a long time. Medical equipment and high-value consumables have always been the focus of Huaying’s investment. It has chosen leading technology and extensive use value. The subject of investment.
Huaying Investment, as the original shareholder of Qihao Medical, led this round of financing, and witnessed that Dr. Pang led the team through product development, clinical and market launch. At present, Qihao Medical has grown into a domestic otolaryngology department with a global leader and originality As a technology platform-based enterprise, Huaying Investment is very pleased to help Qihao Medical to become an industry leader in otolaryngology in China.
Qihao Medical has a full set of ENT products, including plasma systems, fully degradable sinus drug stents and biodegradable swelling hemostatic sponges and other products that have benefited patients, and more excellent products will be launched one after another. The team led by Dr. Pang overcomes difficulties and breaks through the technical threshold, and is expected to provide the best treatment plan for the otolaryngology experts.
Huaying has invested in a number of high-quality projects in otolaryngology, dental medical equipment, and oral cavity. The domestic medical equipment and health care market has a broad market prospect. We firmly believe that medical technology innovation can benefit more consumers.
This round of investor Chuanggu Capital recognized that: From an industry perspective, the clinical unmet demand of otolaryngology is strong, and the competition pattern on the track is scattered. With the further advancement of consumption upgrades, the market size of otolaryngology medical equipment is expected to remain Rapid growth.
From the perspective of the team, Dr. Pang, the founder of Qihao Medical, has many years of experience in clinicians and medical device sales. He not only understands clinical needs, but is also familiar with market sales, and has a leading advantage in product pipeline layout and market promotion. At the same time, Qihao Medical attaches great importance to product R&D and innovation, and its R&D team has outstanding capabilities. It has now developed a number of Class III medical devices with leading advantages, and more innovative products are also under continuous development.
From a business perspective, Qihao Medical is positioned as a specialized company focusing on the R&D, production and sales of ENT medical devices. It is expected to adopt innovative and leading fully degradable sinus drug stent systems, degradable expansible hemostatic sponges and other leading products To fill the unsatisfied market gap in the domestic otolaryngology department, and quickly occupy the market relying on a rich product portfolio.
After Chuanggu Capital invests in Qihao Medical, it will give full play to the resource advantages accumulated by Chuanggu Capital in the medical and health field for many years, and continue to empower the development of Qihao Medical.
This round of investor Baidu Ventures also stated that the prevalence of ENT diseases is high and the population base is huge, but mostly non-life-threatening inflammations, such as sinusitis, otitis media, and tonsillitis. For a long time, the main purpose of clinical treatment is anti-inflammatory, and conservative treatment with hormone drugs is the mainstay. Surgical treatment has a poor prognosis and lacks high-quality high-value consumables. The consumables used in surgery are mostly low-value disposable consumables. In addition, minimally invasive surgery in the Department of Otolaryngology needs to be performed under an endoscope or operating microscope. This type of equipment was previously monopolized by imported manufacturers, and the price is expensive. The doctor's long learning curve restricts the development of the operation.
In recent years, new and high-quality medical equipment products have been continuously launched, which has significantly improved patients’ acceptance of surgery and the effect of disease treatment. Moreover, the domestic substitution of endoscopic equipment has gradually led to the gradual decline of minimally invasive ear, nose and throat surgery, and international equipment giants have begun The ENT equipment market will see rapid growth in the future by investing heavily in the acquisition of high-quality ENT companies and products.
Qihao Medical focuses on the research and development of otolaryngology medical equipment, creating a full product pipeline of "equipment" + "consumables" to increase the influence and penetration of the hospital otolaryngology department. A number of product research and development progress is leading domestically and will be certified within the next two years. At the same time, the company is also seeking the development of original products to maintain the company's differentiation. We are firmly optimistic about the company's potential for continuous development and innovation.
